-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] On March 31, A-shares opened lower and fluctuated overall in early trading, but the traditional Chinese medicine sector remained active.
More than 10 stocks, including Tai'antang, Xinbang Pharmaceutical, and Zhendong Pharmaceutical, were trading at their daily limit, and there was even 1 stock with 5 consecutive boards
.
Among them, Taiantang opened the daily limit on March 31, and has closed 3 daily limit in a row
.
The current price of the stock is 7.
57 yuan per share, and the new market value has reached 5.
804 billion yuan; Yiling Pharmaceutical has once again reached the daily limit
.
The current price is 33.
76 yuan per share, and the market value has reached 56.
4 billion yuan, a new record high; Xinbang Pharmaceutical has hit the daily limit
.
The current price is 6.
61 yuan/share, and the market value is 13.
40 billion yuan; Jilin Aodong closed the daily limit, and is now quoted at 17.
71 yuan/share, with a market value of 20.
6 billion yuan; Zhendong Pharmaceutical opened the daily limit, and the current price is 12.
64 yuan/share, the new The market value is 12.
99 billion yuan; Tonghua Jinma also hit the daily limit today, the current price is 5.
91 yuan per share, and the new market value is 5.
712 billion yuan
.
In addition, Guizhou Bailing’s intraday daily limit today has accumulated 5 consecutive gains, and its stock price has hit a new high in more than a year and a half
.
At present, the stock price is 10.
76 yuan per share, and the new market value is 15.
2 billion yuan
.
In terms of capital, as of 14:18, the net inflow of the main capital of the stock was 39,000 yuan, of which, the net inflow of funds from super large orders was 40,300 yuan, and the net inflow and outflow of funds from large orders was 13.
0767 million yuan
.
In the past 5 trading days, the cumulative net outflow of main funds was 2.
4005 million yuan, the cumulative net inflow of extra-large orders was 266 million yuan, and the cumulative net outflow of large orders was 269 million yuan
.
The data of the Dragon Tiger List shows that the stock has been listed on the Dragon Tiger List 3 times in the past 5 days due to three consecutive trading days, with a cumulative increase of 20% and a daily increase of 7%.
Net sales of 103 million yuan, cumulative net sales of Shenzhen Stock Connect 74.
1091 million yuan, and total net purchases of sales department seats of 174 million yuan
.
On February 26, Guizhou Bailing disclosed its 2021 performance report.
In 2021, the company achieved a total operating income of 3.
093 billion yuan, a year-on-year increase of 0.
17%, and a net profit of 123 million yuan, a year-on-year decrease of 19.
54%
.
It is worth mentioning that Guizhou Bailing has recently issued announcements frequently, among which the announcement on March 29 on the signing of a "Technology Development (Cooperation) Contract" stated that the company recently signed a "Technology Development (Cooperation) Contract" with Liaoning Lida Diabetes Traditional Chinese Medicine Hospital.
Development (Cooperation) Contract", the two parties intend to jointly participate in the research and development of the medical institution preparation "Tangning Tongluo Tablet" project
.
Since March, the company has also issued an announcement on the completion of the transfer of some of the company's shares by the controlling shareholder's agreement, and an announcement on the release of the pledge of some of the controlling shareholder's shares
.
In terms of news, on March 29, the "14th Five-Year Plan for the Development of Traditional Chinese Medicine" was released, which proposed 10 major tasks, set up 15 major development indicators and 11 work columns, and increased the support for the development of Chinese medicine from various aspects.
The support of the traditional Chinese medicine industry helps solve the industry's pain points and promotes the pace of high-quality development of the industry
.
The goal is that by 2025, the health service capacity of traditional Chinese medicine will be significantly enhanced, the high-quality development policy and system of traditional Chinese medicine will be further improved, the revitalization and development of traditional Chinese medicine will achieve positive results, and its unique advantages in the construction of a healthy China will be fully utilized
.
Securities people generally believe that the release of the "14th Five-Year" TCM development plan will be conducive to the healthy and long-term development of the TCM sector, and sectors such as innovative TCM drugs in sub-sectors will benefit
.
With the support of policies and medical insurance, the Chinese medicine industry is expected to usher in an upward turning point in 2022, and the performance is expected to be realized, and the value may be revalued
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
More than 10 stocks, including Tai'antang, Xinbang Pharmaceutical, and Zhendong Pharmaceutical, were trading at their daily limit, and there was even 1 stock with 5 consecutive boards
.
Among them, Taiantang opened the daily limit on March 31, and has closed 3 daily limit in a row
.
The current price of the stock is 7.
57 yuan per share, and the new market value has reached 5.
804 billion yuan; Yiling Pharmaceutical has once again reached the daily limit
.
The current price is 33.
76 yuan per share, and the market value has reached 56.
4 billion yuan, a new record high; Xinbang Pharmaceutical has hit the daily limit
.
The current price is 6.
61 yuan/share, and the market value is 13.
40 billion yuan; Jilin Aodong closed the daily limit, and is now quoted at 17.
71 yuan/share, with a market value of 20.
6 billion yuan; Zhendong Pharmaceutical opened the daily limit, and the current price is 12.
64 yuan/share, the new The market value is 12.
99 billion yuan; Tonghua Jinma also hit the daily limit today, the current price is 5.
91 yuan per share, and the new market value is 5.
712 billion yuan
.
In addition, Guizhou Bailing’s intraday daily limit today has accumulated 5 consecutive gains, and its stock price has hit a new high in more than a year and a half
.
At present, the stock price is 10.
76 yuan per share, and the new market value is 15.
2 billion yuan
.
In terms of capital, as of 14:18, the net inflow of the main capital of the stock was 39,000 yuan, of which, the net inflow of funds from super large orders was 40,300 yuan, and the net inflow and outflow of funds from large orders was 13.
0767 million yuan
.
In the past 5 trading days, the cumulative net outflow of main funds was 2.
4005 million yuan, the cumulative net inflow of extra-large orders was 266 million yuan, and the cumulative net outflow of large orders was 269 million yuan
.
The data of the Dragon Tiger List shows that the stock has been listed on the Dragon Tiger List 3 times in the past 5 days due to three consecutive trading days, with a cumulative increase of 20% and a daily increase of 7%.
Net sales of 103 million yuan, cumulative net sales of Shenzhen Stock Connect 74.
1091 million yuan, and total net purchases of sales department seats of 174 million yuan
.
On February 26, Guizhou Bailing disclosed its 2021 performance report.
In 2021, the company achieved a total operating income of 3.
093 billion yuan, a year-on-year increase of 0.
17%, and a net profit of 123 million yuan, a year-on-year decrease of 19.
54%
.
It is worth mentioning that Guizhou Bailing has recently issued announcements frequently, among which the announcement on March 29 on the signing of a "Technology Development (Cooperation) Contract" stated that the company recently signed a "Technology Development (Cooperation) Contract" with Liaoning Lida Diabetes Traditional Chinese Medicine Hospital.
Development (Cooperation) Contract", the two parties intend to jointly participate in the research and development of the medical institution preparation "Tangning Tongluo Tablet" project
.
Since March, the company has also issued an announcement on the completion of the transfer of some of the company's shares by the controlling shareholder's agreement, and an announcement on the release of the pledge of some of the controlling shareholder's shares
.
In terms of news, on March 29, the "14th Five-Year Plan for the Development of Traditional Chinese Medicine" was released, which proposed 10 major tasks, set up 15 major development indicators and 11 work columns, and increased the support for the development of Chinese medicine from various aspects.
The support of the traditional Chinese medicine industry helps solve the industry's pain points and promotes the pace of high-quality development of the industry
.
The goal is that by 2025, the health service capacity of traditional Chinese medicine will be significantly enhanced, the high-quality development policy and system of traditional Chinese medicine will be further improved, the revitalization and development of traditional Chinese medicine will achieve positive results, and its unique advantages in the construction of a healthy China will be fully utilized
.
Securities people generally believe that the release of the "14th Five-Year" TCM development plan will be conducive to the healthy and long-term development of the TCM sector, and sectors such as innovative TCM drugs in sub-sectors will benefit
.
With the support of policies and medical insurance, the Chinese medicine industry is expected to usher in an upward turning point in 2022, and the performance is expected to be realized, and the value may be revalued
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
